# Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation

Study · id `cardio:ct-nct06632834` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06632834](<https://clinicaltrials.gov/study/NCT06632834>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06632834

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 230 participants.

## Technical summary

Registry record NCT06632834. Allocation not applicable; no masking; primary purpose treatment. Start 2020-08-15 (actual); primary completion 2025-01-19 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 230 participants (planned count; ClinicalTrials.gov record NCT06632834, source copy `cardio:ctgov-nct06632834-2024-10-16`, retrieved 2026-11-18)
- Started: 2020-08-15 (actual) (ClinicalTrials.gov record NCT06632834, source copy `cardio:ctgov-nct06632834-2024-10-16`, retrieved 2026-11-18)
- Primary completion: 2025-01-19 (anticipated) (ClinicalTrials.gov record NCT06632834, source copy `cardio:ctgov-nct06632834-2024-10-16`, retrieved 2026-11-18)
- Completion: 2025-01-19 (anticipated) (ClinicalTrials.gov record NCT06632834, source copy `cardio:ctgov-nct06632834-2024-10-16`, retrieved 2026-11-18)
- Countries: Taiwan (ClinicalTrials.gov record NCT06632834, source copy `cardio:ctgov-nct06632834-2024-10-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06632834-2024-10-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
- Condition: Dilated Cardiomyopathy
- Intervention (Drug): simvastatin therapy
- Lead sponsor: National Taiwan University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Dilated cardiomyopathy (`cardio:dilated-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: National Taiwan University Hospital (`cardio:org-national-taiwan-university-hospital`)

## Provenance

Content hash: f53bf742131d691cea2e81479d30097abc2f85caae4d1660d8de47881b61f655
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
